HM 100168
Alternative Names: HM-100168Latest Information Update: 11 Jul 2024
At a glance
- Originator Hanmi Pharmaceutical
- Class Antineoplastics
- Mechanism of Action ERN1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours